admin – Page 3315 – Get News Story

“Don’t Mess with Anna” Receives Literary Titan Gold Book Award for Its Genre-Bending Fantasy of Vengeance and Magic

Celeste Prater’s gripping fantasy novel DON’T MESS WITH ANNA: A RECKONING IN BLOOD AND INK has been awarded the Literary Titan Gold Book Award, a distinction reserved for books that exemplify exceptional writing, vivid storytelling, and powerful originality.

In a saturated market of formulaic fantasy, Don’t Mess with Anna breaks the mold. The story follows Anna DeMarco, a gifted writer whose creative life is shattered by a cruel online troll, Milton Smith. But when Milton goes too far, karma intervenes with a vengeance. Thrust into a savage medieval world shaped by Anna’s own pen and powered by retribution and magic, Milton becomes a prisoner of the very fantasies he mocked. What begins as poetic justice unfolds into a brutal journey of reckoning, as the troll becomes the tortured.

This modern-day revenge fantasy has drawn rave critical acclaim. Literary Titan praised the novel as “a wild, genre-melting ride”, describing it as a brutal and darkly hilarious takedown of internet toxicity: “It’s messy, chaotic, wildly entertaining, and unexpectedly sharp… perfect for anyone who’s ever read a one-star review and thought, ‘Wow, who hurt you?’”

Reviewers have highlighted Prater’s relentless pacing, visceral writing style, and a vividly cruel fantasy realm where gallantry is dead and justice is anything but subtle. At once a savage critique of online cruelty and a thrilling adventure with teeth, Don’t Mess with Anna delivers a fierce, genre-blending punch.

Don’t Mess with Anna is a fully human-powered creation—a tale grown from grit, imagination, and raw emotional truth. The award underscores Prater’s ability to take modern anxieties and distill them into compelling, unforgettable narratives that resonate with readers across genres.

Ready to dive into a dark fantasy like no other? Don’t Mess with Anna: A Reckoning In Blood And Ink is available now on Amazon in Kindle and paperback formats. Whether you crave a razor-sharp tale of revenge, twisted magic, or a brutally satisfying takedown of online cruelty, this award-winning novel delivers it all. Don’t miss the story everyone’s calling “bonkers in the best way.” Grab your copy today and experience the reckoning for yourself.

About the Author

Celeste Prater is a multi-award-winning author known for her ability to conjure mesmerizing worlds and unforgettable characters. Her unique writing style has earned her numerous accolades, including “Top Pick,” “Choice Award,” “ABR Award,” “Book of the Month,” “Best Banter,” and international honors like the “Readers’ Favorite” 5-Star distinction, as well as the recent Literary Titan Book Award. Celeste’s stories are a masterclass in genre fusion, deftly blending action, suspense, and dark humor with richly imagined settings. Whether she’s crafting gripping fantasy or high-stakes romance, her work resonates with readers who crave bold storytelling with heart and bite.

Want to explore more of Celeste Prater’s unforgettable worlds? Visit her official website to learn about her full catalog of award-winning books, dive into behind-the-scenes insights, and read her latest blog posts on writing, inspiration, and storytelling. Start your journey at celesteprater.com and connect with the imagination behind the magic.

Media Contact
Company Name: Literary Titan
Contact Person: Celeste Prater
Email: Send Email
Country: United States
Website: http://www.celesteprater.com/

Michael L. Kaufman’s Doing Good & Doing Well Wins Prestigious Book Excellence Award, Empowering Helping Professionals to Lead and Effect Change

Doing Good & Doing Well: Inspiring Helping Professionals to Become Leaders in Their Organizations is recognized for its outstanding writing, design, and overall market appeal out of thousands of books submitted into the Book Excellence Awards.

Doing Good & Doing Well: Inspiring Helping Professionals to Become Leaders in Their Organizations, written by in-the-field social worker turned CEO Michael L. Kaufman, MSW, PhD, is an empowering guide for all types of members of the helping professions who dedicate their lives to serving others. Combining practical insights and inspirational stories, the book champions the untapped leadership potential of those in the social services—from social workers, educators, counselors, and therapists to healthcare and wellness specialists, advocates, and community service workers—encouraging them to apply their specific training, acquired aptitudes, and natural traits in pursuit of leadership roles in service-based organizations. The book was named a Winner in the Career category of the Book Excellence Awards. The awards competition is dedicated to recognizing both independent and traditionally published authors and publishers for excellence in writing, design, and overall market appeal in over 100 countries around the world.

“To learn that my book has been recognized as a helpful career tool is both delightfully surprising and tremendously gratifying,” says Kaufman. With over 30 years of experience spanning social work, education, and executive leadership, Kaufman draws from his personal journey to provide guidance for others seeking to make a broader impact. “What matters most to me at this point in my professional development is getting the message out about the incredible leadership potential talented and qualified helping professionals possess. To earn an award for that mission has made me quite happy and proud—it’s the best kind of icing on the cake I’m working to bake, and I’m immensely grateful.”

Doing Good & Doing Well showcases how servant leadership qualities including empathy, active listening, critical thinking, crisis management, and community building translate seamlessly into effective leadership. “Helping professionals are everyday heroes,” Kaufman states. “Many don’t realize they have the skills to lead organizations and create systemic change. This book is about helping them recognize their power and take their careers to new heights while staying true to their mission of improving lives.” Through personal anecdotes, case studies, and cultural insights, the book provides readers with practical advice to transition from the frontlines to leadership roles and how to advocate for their own career advancement even as they continue to advocate for the populations they serve.

“The world needs compassionate, fair-minded, emotionally intelligent leaders more than ever,” Kaufman shares. “I’m committed to shining a light on just how much helpers bring to the table for those who make organizational hire decisions, but also for the helpers themselves, who are often too humble and service-oriented to see the tremendous value of their particular skill sets.”

The book has received widespread praise for its highly accessible and relatable approach to leadership development. Amanda Semetko, SLP.D., CCC-SLP, praised the book as “a fresh perspective on leadership … that provides valuable lessons and inspiration … a valuable resource that will undoubtedly leave a lasting impact on its readers.” And Jennine Estes, MFT, of Estes Therapy, called it, “a must-read for any helping professional planning to grow their company through positive leadership.” Additional professional endorsements and customer reviews speak to a book that’s warm, authentic, helpful, and, especially, empowering—delivered from one helping professional to another.

Doing Good & Doing Well is available from Amazon, Barnes & Noble, Rowman & Littlefield, and other major retailers. For more information about the book and to learn more about Dr. Kaufman’s work, visit www.michaellkaufman.com or connect with him on social media on LinkedIn, Instagram, and TikTok.

About Michael L. Kaufman

Michael L. Kaufman, MSW, PhD, combines the heart of a social worker with the head of a business executive to lead companies, effect change, and improve lives.

As Managing Director of Premier Education Partners, Mike is committed to transforming the lives of K–12+ students with special needs through innovative and impactful educational programs. His leadership journey includes a career-defining tenure as the head of Specialized Education Services Inc., a private special education organization of day schools that grew to 75+ programs under his leadership, and the launch of TalkPath™ Live, a teletherapy company that has delivered tens of thousands of in-school support services sessions for students nationwide.

Mike’s diverse expertise stems from degrees in accounting, social work, and clinical psychology, along with completing Harvard Business School’s prestigious Key Executives Program. A sought-after speaker, thought leader, and educator, he has taught graduate-level courses at Rutgers University and continues to inspire through his mentorship, advocacy, and focus on meaningful change in education and beyond.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Michael L. Kaufman’s Doing Good & Doing Well Wins Prestigious Book Excellence Award, Empowering Helping Professionals to Lead and Effect Change

Congenital Ichthyosis Market on Track for Major Expansion by 2032, According to DelveInsight | Krystal Biotech, Timber pharmaceuticals

The Key Congenital Ichthyosis Companies in the market include – Krystal Biotech, Timber pharmaceuticals, and others.

The Congenital Ichthyosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Congenital Ichthyosis pipeline products will significantly revolutionize the Congenital Ichthyosis market dynamics.

DelveInsight’s “Congenital Ichthyosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Congenital Ichthyosis, historical and forecasted epidemiology as well as the Congenital Ichthyosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Congenital Ichthyosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Congenital Ichthyosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Congenital Ichthyosis Market Forecast

Some of the key facts of the Congenital Ichthyosis Market Report:

The Congenital Ichthyosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In August 2024, A year after investing in Timber Pharmaceuticals’ dermatology pipeline, Leo Pharma announced a Phase III setback for its lead asset, TMB-001. The topical isotretinoin ointment failed to show significant benefit in patients with moderate to severe congenital ichthyosis—a group of inherited skin disorders causing dry, scaly skin. In the Phase III ASCEND trial (NCT05295732), the treatment did not achieve statistically significant improvements over the vehicle, resulting in the failure to meet both primary and key secondary endpoints.
According to Ginarte et al., in the United States, a prevalence at birth of 1 per 100,000 population for Lamellar Ichthyosis (LI) and of 1 per 200,000 population for congenital Ichthyosiform Erythroderma (CIE) has been estimated.
As per the British Association of Dermatologists, Lamellar Ichthyosis is a rare form occurring in 1 in 200,000 live births in the United Kingdom
Key Congenital Ichthyosis Companies: Krystal Biotech, Timber pharmaceuticals, and others
Key Congenital Ichthyosis Therapies: KB105, TMB-001, and others
The Congenital Ichthyosis epidemiology based on severity-specific cases analyzed that about 2/3rd of the patients suffered from moderate to severe illness

Congenital Ichthyosis Overview

Ichthyosis is a group of keratinization disorders that is clinically and etiologically heterogeneous and characterized by dryness, flaking, and peeling of the skin. Due to abnormalities in the structure of the stratum corneum, the increased transepidermal water loss causes excessive dryness. There are congenital and acquired forms of the disease.

Congenital from of ichthyosis can be defined as a group of monogenetic disorders of cornification, sometimes associated with systemic symptoms.

Request a sample for the Triple X Syndrome Market Report: https://www.delveinsight.com/report-store/congenital-ichthyosis-market

Congenital Ichthyosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Download the report to understand which factors are driving Congenital Ichthyosis epidemiology trends @ Congenital Ichthyosis Epidemiology Forecast

Congenital Ichthyosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Congenital Ichthyosis market or expected to get launched during the study period. The analysis covers Congenital Ichthyosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Congenital Ichthyosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Congenital Ichthyosis Therapies and Key Companies

KB105: Krystal Biotech
TMB-001: Timber pharmaceuticals

Discover more about therapies set to grab major Congenital Ichthyosis market share @ Congenital Ichthyosis Treatment Landscape

Congenital Ichthyosis Market Drivers

Important progress has been made regarding understanding disease pathology, diagnosis, and treatment effects in Congenital Ichthyosis
Population rates of Congenital Ichthyosis in children and young people have been investigated in several countries
Many therapies are under investigation in various phases of clinical trials. These include TMB-001, KB105

Congenital Ichthyosis Market Barriers

Challenges in Congenital Ichthyosis diagnosis
Development of novel Congenital Ichthyosis therapies
Limitations in gene therapy
Poor disease understanding
Clinical biomarkers

Scope of the Congenital Ichthyosis Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Congenital Ichthyosis Companies: Krystal Biotech, Timber pharmaceuticals, and others
Key Congenital Ichthyosis Therapies: KB105, TMB-001, and others
Congenital Ichthyosis Therapeutic Assessment: Congenital Ichthyosis current marketed and Congenital Ichthyosis emerging therapies
Congenital Ichthyosis Market Dynamics: Congenital Ichthyosis market drivers and Congenital Ichthyosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Congenital Ichthyosis Unmet Needs, KOL’s views, Analyst’s views, Congenital Ichthyosis Market Access and Reimbursement

To know more about Congenital Ichthyosis companies working in the treatment market, visit @ Congenital Ichthyosis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Congenital Ichthyosis Market Report Introduction

2. Executive Summary for Congenital Ichthyosis

3. SWOT analysis of Congenital Ichthyosis

4. Congenital Ichthyosis Patient Share (%) Overview at a Glance

5. Congenital Ichthyosis Market Overview at a Glance

6. Congenital Ichthyosis Disease Background and Overview

7. Congenital Ichthyosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Congenital Ichthyosis

9. Congenital Ichthyosis Current Treatment and Medical Practices

10. Congenital Ichthyosis Unmet Needs

11. Congenital Ichthyosis Emerging Therapies

12. Congenital Ichthyosis Market Outlook

13. Country-Wise Congenital Ichthyosis Market Analysis (2019–2032)

14. Congenital Ichthyosis Market Access and Reimbursement of Therapies

15. Congenital Ichthyosis Market Drivers

16. Congenital Ichthyosis Market Barriers

17. Congenital Ichthyosis Appendix

18. Congenital Ichthyosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Congenital Ichthyosis Market on Track for Major Expansion by 2032, According to DelveInsight | Krystal Biotech, Timber pharmaceuticals

Triple X Syndrome Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Hoffmann-La Roche Ltd., Invitae Corporation, LLumina Inc, Natera Inc, Progenity Inc, perkin Elmer

The Key Triple X Syndrome Companies in the market include – Hoffmann-La Roche Ltd., Invitae Corporation, LLumina Inc, Natera Inc, Progenity Inc, perkin Elmer, and others.

The Triple X Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Triple X Syndrome market dynamics.

DelveInsight’s “Triple X Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Triple X Syndrome, historical and forecasted epidemiology as well as the Triple X Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Triple X Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Triple X Syndrome Market Forecast

Some of the key facts of the Triple X Syndrome Market Report:

The Triple X Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
Chromosome abnormalities is an uncommon genetic condition known as Triple X Syndrome. About 1 in 1000 females are affected by it.
The triple X syndrome treatment market is divided into periodic screening, educational support, early intervention services, and supportive environments based on the type of treatment
The triple X syndrome therapy market is divided into hospitals, specialty clinics, and other end-users based on end-users
The triple X syndrome treatment market has been divided into hospital pharmacy, retail pharmacy, and others based on the distribution channel
Key Triple X Syndrome Companies: Hoffmann-La Roche Ltd., Invitae Corporation, LLumina Inc, Natera Inc, Progenity Inc, perkin Elmer, and others

Key Triple X Syndrome Therapies: Non invasive prenatal diagnosis, and others
The Triple X Syndrome Treatment Market study also provides data on free market activity, import/trade utilization, cost, value, volume, and gross margins.

Triple X Syndrome Overview

About 1 in 1,000 girls have triple X syndrome, commonly known as trisomy X or 47,XXX, which is a genetic condition. All of a woman’s cells typically include two X chromosomes, one from each father. A female with triple X syndrome carries three X chromosomes.

Request a sample for the Triple X Syndrome Market Report:

https://www.delveinsight.com/report-store/triple-x-syndrome-market

Triple X Syndrome Epidemiology

Download the report to understand which factors are driving Triple X Syndrome epidemiology trends @ Triple X Syndrome Epidemiology Forecast

Triple X Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Triple X Syndrome market or expected to get launched during the study period. The analysis covers Triple X Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Triple X Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Triple X Syndrome Therapies and Key Companies

Non invasive prenatal diagnosis: University Hospital, Montpellier

Discover more about therapies set to grab major Triple X Syndrome market share @ Triple X Syndrome Medications

Scope of the Triple X Syndrome Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Triple X Syndrome Companies: Hoffmann-La Roche Ltd., Invitae Corporation, LLumina Inc, Natera Inc, Progenity Inc, perkin Elmer, and others
Key Triple X Syndrome Therapies: Non invasive prenatal diagnosis, and others
Therapeutic Assessment: Triple X Syndrome current marketed and Triple X Syndrome emerging therapies
Triple X Syndrome Market Dynamics: Triple X Syndrome market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Triple X Syndrome Unmet Needs, KOL’s views, Analyst’s views, Triple X Syndrome Market Access and Reimbursement

To know more about Triple X Syndrome companies working in the treatment market, visit @ Triple X Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents

1. Triple X Syndrome Market Report Introduction

2. Executive Summary for Triple X Syndrome

3. SWOT analysis of Triple X Syndrome

4. Triple X Syndrome Patient Share (%) Overview at a Glance

5. Triple X Syndrome Market Overview at a Glance

6. Triple X Syndrome Disease Background and Overview

7. Triple X Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Triple X Syndrome

9. Triple X Syndrome Current Treatment and Medical Practices

10. Triple X Syndrome Unmet Needs

11. Triple X Syndrome Emerging Therapies

12. Triple X Syndrome Market Outlook

13. Country-Wise Triple X Syndrome Market Analysis (2019–2032)

14. Triple X Syndrome Market Access and Reimbursement of Therapies

15. Triple X Syndrome Market drivers

16. Triple X Syndrome Market barriers

17. Triple X Syndrome Appendix

18. Triple X Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Triple X Syndrome Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Hoffmann-La Roche Ltd., Invitae Corporation, LLumina Inc, Natera Inc, Progenity Inc, perkin Elmer

Cognitive Impairment Associated with Schizophrenia Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Cyclerion Therapeutics, Biogen, Neurocrine

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cognitive Impairment Associated with Schizophrenia pipeline constitutes 3+ key companies continuously working towards developing 3+ Cognitive Impairment Associated with Schizophrenia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Cognitive Impairment Associated with Schizophrenia Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cognitive Impairment Associated with Schizophrenia Market.

The Cognitive Impairment Associated with Schizophrenia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Cognitive Impairment Associated with Schizophrenia Pipeline Report:

Companies across the globe are diligently working toward developing novel Cognitive Impairment Associated with Schizophrenia treatment therapies with a considerable amount of success over the years.
Cognitive Impairment Associated with Schizophrenia companies working in the treatment market are Autifony Therapeutics, Cyclerion Therapeutics, Biogen, Neurocrine Biosciences, Recognify Life Sciences, Boehringer Ingelheim, Memory Pharmaceuticals, Amarantus BioScience, Neurocrine Biosciences, Hoffmann-La Roche, Eli Lilly and Company, Cephalon, Johnson & Johnson Pharma, and others, are developing therapies for the Cognitive Impairment Associated with Schizophrenia treatment

Emerging Cognitive Impairment Associated with Schizophrenia therapies in the different phases of clinical trials are- Research programme, CY6463, BIIB104, Luvadaxistat, RL-007, Iclepertin, MEM 3454, Eltoprazine, Luvadaxistat, Basmisanil, LY500307, armodafinil, Extended-release galantamine hydrobromide, and others are expected to have a significant impact on the Cognitive Impairment Associated with Schizophrenia market in the coming years.
In January 2025, Boehringer Ingelheim reported top-line results from its Phase III CONNEX clinical program assessing iclepertin for cognitive impairment in adults with schizophrenia. The study did not meet its primary or key secondary endpoints. After six months, no statistically significant improvements in cognition or functioning were observed in patients receiving iclepertin compared to placebo. However, across all three trials, iclepertin—a glycine transporter 1 (GlyT1) inhibitor—was generally well tolerated, and its safety profile remained consistent with earlier research.
In December 2024, Kynexis, a biotech company specializing in precision treatments for brain disorders, has announced encouraging topline results from its first-in-human Phase 1 clinical trial. The study, conducted in healthy volunteers, assessed the safety, tolerability, and pharmacokinetics of KYN-5356—an innovative, first-in-class oral small molecule KAT-II inhibitor being developed for cognitive impairment associated with schizophrenia (CIAS). The trial included both single and multiple ascending dose evaluations. In addition, the multiple ascending dose phase explored central pharmacodynamic biomarkers and cognitive performance to confirm target engagement.
In Sepetmber 2024, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced that its Phase 2 ERUDITE™ clinical trial evaluating the investigational drug luvadaxistat (NBI-1065844) did not achieve its primary goal of improving cognitive impairment in individuals with schizophrenia. This was the second Phase 2 trial for luvadaxistat, following the earlier INTERACT™ study. However, the ERUDITE trial failed to reproduce the positive cognitive outcomes previously observed, potentially due to significant variability in cognitive assessments among participants and possible imbalances in baseline characteristics across treatment groups
In April 2024, Alto Neuroscience has announced positive outcomes from its Phase I clinical trial of the PDE4 inhibitor ALTO-101 for treating cognitive impairment associated with schizophrenia (CIAS). The study showed that ALTO-101, delivered via a transdermal delivery system (TDS), had better tolerability and improved pharmacokinetics compared to oral administration. The Phase I trial aimed to evaluate the safety, tolerability, pharmacokinetics, and adhesion properties of the transdermal formulation of ALTO-101, in contrast to its oral form, in healthy volunteers.

Cognitive Impairment Associated with Schizophrenia Overview

Cognitive impairment associated with schizophrenia (CIAS) refers to the deficits in various cognitive functions experienced by individuals with schizophrenia. These cognitive deficits are a core feature of the disorder and can significantly impact daily functioning, social interactions, and overall quality of life.

Get a Free Sample PDF Report to know more about Cognitive Impairment Associated with Schizophrenia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cognitive-impairment-associated-with-schizophrenia-cias-pipeline-insight

Emerging Cognitive Impairment Associated with Schizophrenia Drugs Under Different Phases of Clinical Development Include:

Research programme: Autifony Therapeutics
CY6463: Cyclerion Therapeutics
BIIB104: Biogen
Luvadaxistat: Neurocrine Biosciences
RL-007: Recognify Life Sciences
Iclepertin: Boehringer Ingelheim
MEM 3454: Memory Pharmaceuticals
Eltoprazine: Amarantus BioScience
Luvadaxistat: Neurocrine Biosciences
Basmisanil: Hoffmann-La Roche
LY500307: Eli Lilly and Company
armodafinil: Cephalon
Extended-release galantamine hydrobromide: Johnson & Johnson Pharma
Luvadaxistat: Takeda

Cognitive Impairment Associated with Schizophrenia Route of Administration

Cognitive Impairment Associated with Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Cognitive Impairment Associated with Schizophrenia Molecule Type

Cognitive Impairment Associated with Schizophrenia Products have been categorized under various Molecule types, such as

Oligonucleotide
Peptide
Small molecule

Cognitive Impairment Associated with Schizophrenia Pipeline Therapeutics Assessment

Cognitive Impairment Associated with Schizophrenia Assessment by Product Type
Cognitive Impairment Associated with Schizophrenia By Stage and Product Type
Cognitive Impairment Associated with Schizophrenia Assessment by Route of Administration
Cognitive Impairment Associated with Schizophrenia By Stage and Route of Administration
Cognitive Impairment Associated with Schizophrenia Assessment by Molecule Type
Cognitive Impairment Associated with Schizophrenia by Stage and Molecule Type

DelveInsight’s Cognitive Impairment Associated with Schizophrenia Report covers around 3+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Cognitive Impairment Associated with Schizophrenia product details are provided in the report. Download the Cognitive Impairment Associated with Schizophrenia pipeline report to learn more about the emerging Cognitive Impairment Associated with Schizophrenia therapies

Some of the key companies in the Cognitive Impairment Associated with Schizophrenia Therapeutics Market include:

Key companies developing therapies for Cognitive Impairment Associated with Schizophrenia are – Autifony Therapeutics Ltd, Boehringer Ingelheim International GmbH, Neurocrine Biosciences Inc, Novartis AG, Suven Life Sciences Ltd, Accure Therapeutics SL, Anvyl LLC, Astellas Pharma Inc, AstraZeneca Plc, Atai Life Sciences NV, and others.

Cognitive Impairment Associated with Schizophrenia Pipeline Analysis:

The Cognitive Impairment Associated with Schizophrenia pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Cognitive Impairment Associated with Schizophrenia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cognitive Impairment Associated with Schizophrenia Treatment.
Cognitive Impairment Associated with Schizophrenia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Cognitive Impairment Associated with Schizophrenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cognitive Impairment Associated with Schizophrenia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cognitive Impairment Associated with Schizophrenia drugs and therapies

Cognitive Impairment Associated with Schizophrenia Pipeline Market Drivers

Increase in Prevalence of Mental Disturbances, rise in Awareness About Mental Health are some of the important factors that are fueling the Cognitive Impairment Associated with Schizophrenia Market.

Cognitive Impairment Associated with Schizophrenia Pipeline Market Barriers

However, side-effects associated with the treatment of Cognitive Impairment Associated with Schizophrenia, stigma associated with mental illness and other factors are creating obstacles in the Cognitive Impairment Associated with Schizophrenia Market growth.

Scope of Cognitive Impairment Associated with Schizophrenia Pipeline Drug Insight

Coverage: Global
Key Cognitive Impairment Associated with Schizophrenia Companies: Autifony Therapeutics, Cyclerion Therapeutics, Biogen, Neurocrine Biosciences, Recognify Life Sciences, Boehringer Ingelheim, Memory Pharmaceuticals, Amarantus BioScience, Neurocrine Biosciences, Hoffmann-La Roche, Eli Lilly and Company, Cephalon, Johnson & Johnson Pharma, and others
Key Cognitive Impairment Associated with Schizophrenia Therapies: Research programme, CY6463, BIIB104, Luvadaxistat, RL-007, Iclepertin, MEM 3454, Eltoprazine, Luvadaxistat, Basmisanil, LY500307, armodafinil, Extended-release galantamine hydrobromide, and others
Cognitive Impairment Associated with Schizophrenia Therapeutic Assessment: Cognitive Impairment Associated with Schizophrenia current marketed and Cognitive Impairment Associated with Schizophrenia emerging therapies
Cognitive Impairment Associated with Schizophrenia Market Dynamics: Cognitive Impairment Associated with Schizophrenia market drivers and Cognitive Impairment Associated with Schizophrenia market barriers

Request for Sample PDF Report for Cognitive Impairment Associated with Schizophrenia Pipeline Assessment and clinical trials

Table of Contents

1. Cognitive Impairment Associated with Schizophrenia Report Introduction

2. Cognitive Impairment Associated with Schizophrenia Executive Summary

3. Cognitive Impairment Associated with Schizophrenia Overview

4. Cognitive Impairment Associated with Schizophrenia- Analytical Perspective In-depth Commercial Assessment

5. Cognitive Impairment Associated with Schizophrenia Pipeline Therapeutics

6. Cognitive Impairment Associated with Schizophrenia Late Stage Products (Phase II/III)

7. Cognitive Impairment Associated with Schizophrenia Mid Stage Products (Phase II)

8. Cognitive Impairment Associated with Schizophrenia Early Stage Products (Phase I)

9. Cognitive Impairment Associated with Schizophrenia Preclinical Stage Products

10. Cognitive Impairment Associated with Schizophrenia Therapeutics Assessment

11. Cognitive Impairment Associated with Schizophrenia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cognitive Impairment Associated with Schizophrenia Key Companies

14. Cognitive Impairment Associated with Schizophrenia Key Products

15. Cognitive Impairment Associated with Schizophrenia Unmet Needs

16 . Cognitive Impairment Associated with Schizophrenia Market Drivers and Barriers

17. Cognitive Impairment Associated with Schizophrenia Future Perspectives and Conclusion

18. Cognitive Impairment Associated with Schizophrenia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cognitive Impairment Associated with Schizophrenia Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Cyclerion Therapeutics, Biogen, Neurocrine

StriveWell Opens 2nd Franchise Location, SweatHouz (SWTHZ) Short Hills

“We’re thrilled to bring SWTHZ’s premium contrast therapy experience to Short Hills. This studio embodies our vision for holistic wellness, and it’s just the beginning. SWTHZ Tribeca in Q4 2025 and SWTHZ Morristown in Q4 2025 are coming soon. StriveWell is also bringing an innovative Row Former workout, STRONG Pilates, reformer-inspired and cardio-infused. We believe this brand will complete our stake in SWTHZ and create a platform of brands focused on recovery, longevity, and low-impact fitness.”

StriveWell announces the grand opening of its newest SweatHouz (SWTHZ) wellness studio in Short Hills, New Jersey. The studio, which features innovative contrast therapy and luxury amenities, is part of its rapid expansion.

Springfield, NJ – May 12, 2025 – StriveWell, a multi-unit franchise investment group, opens its second location, SWTHZ Short Hills, a new premium wellness studio in Springfield, NJ. They will celebrate their grand opening on Monday, May 12, 2025, with a ribbon-cutting ceremony from 3 to 5 p.m. This event invited the local community of Short Hills and greater Millburn, New Jersey, to tour the facility at 92 Millburn Avenue – part of The Metropolitan development, A Garden Communities property. Each guest will enjoy a tour of our private luxury suite equipped with a Spectra S10 Pro Redlight Therapy Bed, Infrared Sauna, Cold Plunge, and Vitamin C-infused shower.

Premium Contrast Therapy Experience

SWTHZ Short Hills offers each member a private, guided contrast therapy experience. In this modern take on an age-old practice, members move between a heated infrared sauna and a chilled cold plunge at 47 degrees, followed by a refreshing vitamin C shower. Studio staff walk members through the session in a suite-style setting, ensuring safety and comfort. “We want to make the experience as personal and restorative as possible while providing a private luxury setting,” notes StriveWell CEO Rico Macaraeg. This emphasis on service and luxury, in each one-person suite, has become a hallmark of SWTHZ.

Science-Backed Wellness Benefits

The SWTHZ offering is aligned with growing research on deliberate exposure to hot-and-cold therapy. Medical experts report that regular infrared sauna use can relieve pain, improve circulation, and even boost immune function by increasing white blood cell production. Likewise, full-body cold plunges are credited with constricting blood vessels (aiding circulation), reducing inflammation, and speeding muscle recovery. The Massachusetts General Hospital notes that combining sauna and cold treatments can “boost cardiovascular health, reduce inflammation, and aid muscle recovery.” Peer-reviewed studies also show long-term health advantages: a JAMA Internal Medicine study linked frequent sauna bathing to lower risk of cardiovascular death, and a Neurology study found reduced stroke risk among people who took regular saunas. In short, SWTHZ’s contrast therapy is built on a scientifically informed approach to recovery and longevity, rather than fad.

StriveWell’s Expansion and Future Plans of SWTHZ & STRONG Pilates

“We’re thrilled to bring SWTHZ’s premium contrast therapy experience to Short Hills,” said Rico Macaraeg, CEO of StriveWell. “This studio embodies our vision for holistic wellness, and it’s just the beginning. Coming soon are SWTHZ Tribeca in Q4 2025 and SWTHZ Morristown in Q4 2025. StriveWell is also bringing an innovative RowFormer workout, STRONG Pilates, reformer inspired, cardio infused. The international pilates brand brings pilates, rowing, cycling and weights in their 60 min classes around the world. “We believe this brand will complete our stake in SWTHZ and create a platform of brands focused on recovery, longevity and low-impact fitness brands.” Macaraeg’s comment underscores both brands’ growth: especially with the StriveWell launch of SWTHZ FlagShip in Tribeca, NYC. StriveWell is expanding the STRONG pilates US launch with opening STRONG Garwood in Q2 2025, STRONG Morristown in Q4 2025 STRONG Monmouth in Q2 2026. This wave of openings reflects a broader strategy: StriveWell is rapidly scaling brands that blend boutique fitness with recovery, mirroring global wellness trends.

StriveWell attributes its real estate success to real estate partner, Rob Mackowski, of Pierson Commercial for all real estate transactions and Daniel Le Duc & Dylan Hammer of D&D Construction Management for build management which allows for StriveWell to continue to hit development schedules of opening 1 location per quarter.

About StriveWell

StriveWell is an investor and operator focused on building and growing innovative franchise brands in the health, wellness, and fitness sectors. StriveWell’s mission is to deliver fitness and recovery brands that empower individuals to prioritize recovery and longevity. With SweatHouz (SWTHZ) and STRONG Pilates as its cornerstone brands, StriveWell is taking a central role in transforming wellness culture. StriveWell’s mission is “rooted in community, recovery, and longevity,” focusing on “brands that go beyond fitness. Brands that redefine what it means to care for the body, mind, and spirit.”

Media Contact
Company Name: StriveWell
Contact Person: Zuhura Miriam
Email: Send Email
Phone: (201) 515-5516
Country: United States
Website: www.strivewell.co

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: StriveWell Opens 2nd Franchise Location, SweatHouz (SWTHZ) Short Hills

Golden Years Home Care Expands Accessibility to 24-Hour Home Care in San Diego.

Ensuring families in San Diego have round-the-clock support for their elderly loved ones.

San Diego, CA – Golden Years Home Care is proud to reaffirm its commitment to helping families in San Diego by continuing to offer 24-hour home care services. Designed to provide comprehensive care for seniors, this initiative addresses the growing need for reliable, round-the-clock caregiving, ensuring that elderly individuals receive the support they need in the comfort of their homes.

“At Golden Years Home Care, we understand the challenges families face when caring for their aging loved ones,” said Ken Ballard, owner of Golden Years Home Care. “Our mission is to offer peace of mind by delivering high-quality care tailored to individual needs. Whether managing chronic conditions or providing daily assistance, we are dedicated to enhancing the quality of life for seniors in San Diego.”

Golden Years Home Care’s 24-hour care for the elderly in San Diego is especially beneficial for individuals with complex medical conditions, dementia, or those recovering from hospital stays. These services are delivered by highly skilled and compassionate caregivers trained to prioritize safety, comfort, and independence.

Unparalleled Safety and Emergency Response: 24-hour home care ensures immediate assistance during falls, medical emergencies, or other unforeseen circumstances. This constant supervision minimizes risks, offering families peace of mind, knowing their loved ones are in capable hands at all times.

Personalized and Consistent Support: Unlike assisted living facilities, where care may be generalized, 24-hour home care provides tailored assistance that aligns with each individual’s needs. Caregivers ensure continuity and familiarity from meal preparation to medication management, building trust and understanding with their clients.

Preserving Independence and Comfort: Remaining in a familiar environment is vital to a senior’s emotional and mental well-being. 24-hour home care allows elderly individuals to maintain their routines and independence while receiving the necessary support, fostering a sense of dignity and control over their lives.

Benefits of the 24-Hour Care Program:

Personalized Assistance: Tailored care plans designed for the unique needs of each senior.
Peace of Mind for Families: Round-the-clock care ensures families can focus on other responsibilities.
Improved Quality of Life: Seniors remain in a familiar environment while receiving the support they need.

For more information about Golden Years Home Care and their 24-hour home care in San Diego, CA, please visit their website at https://goldenyearshomecare.com/san-diego-ca.

About Golden Years Home Care:

Golden Years Home Care is a leading provider of in-home care services in San Diego, CA. Specializing in compassionate, professional caregiving, it offers a wide range of services to meet the diverse needs of the elderly community. From managing chronic conditions to providing companionship, its mission is to enable seniors to live independently and comfortably in their homes.

Media Contact
Company Name: Golden Years Home Care (San Diego, CA)
Contact Person: Ken Ballard
Email: Send Email
Phone: (916) 333-0383
Address:301 SPRUCE ST, STE 101
City: San Diego
State: California 92103-5626
Country: United States
Website: https://goldenyearshomecare.com/san-diego-ca/

EULA Home Care Agency Delivers Exceptional Senior Home Care Services in Charlotte, NC

Personalized care solutions to help seniors thrive comfortably at home

Charlotte, NC – EULA Home Care, a trusted Charlotte senior home care agency, is proud to announce its commitment to delivering personalized care solutions for seniors in Charlotte, NC. As of November 2024, the agency offers tailored services that enable elderly clients to enjoy an enhanced quality of life while remaining comfortably in their own homes. EULA Home Care’s approach focuses on compassionate care designed to meet the individual needs of seniors and their families.

“At EULA Home Care, we believe that every senior deserves the opportunity to age with dignity and comfort in the familiar surroundings of their home. Our team is dedicated to providing personalized care solutions that support seniors’ independence and well-being,” said Davetta Williams, owner of EULA Home Care. “We understand that every client has unique needs, and we strive to deliver care that respects their individuality and enhances their quality of life.”

With a growing need for Charlotte senior home care, EULA Home Care offers services that include daily living assistance, companionship, and specialized care for those with chronic conditions. These services are tailored to help seniors remain home rather than move to institutional care settings. The agency’s caregivers are trained professionals who provide not only physical support but also emotional and social engagement, fostering a holistic approach to senior care.

One of the key benefits of compassionate and professional senior home care is the sense of security it provides to families. Knowing that their loved ones are in the hands of trained and caring professionals allows families to have peace of mind. EULA Home Care’s caregivers are skilled at addressing both routine tasks and unexpected challenges, ensuring that seniors receive consistent, reliable support.

Professional senior home care also promotes a higher quality of life for seniors. Personalized care plans mean seniors receive assistance tailored to their needs, preferences, and medical conditions. Whether it’s help with medication management, mobility support, or engaging in meaningful activities, EULA Home Care ensures that seniors can maintain their routines and enjoy a sense of independence and dignity.

Furthermore, compassionate caregivers provide crucial emotional support that goes beyond physical care. Seniors often experience isolation or loneliness; having a caregiver who offers companionship and empathy can make a profound difference. Consistent social interaction helps improve mental well-being, reduce anxiety, and foster a sense of connection and joy.

Families seeking trusted home care agency services in Charlotte, NC, can rely on EULA Home Care for dependable, compassionate, and high-quality care. For more information about the company and their senior home care in Charlotte, NC, please visit their website at https://eulahomecare.com.

About EULA Home Care Agency:

EULA Home Care is a leading provider of senior home care services in Charlotte, NC. Focused on enhancing seniors’ quality of life, the agency offers personalized and compassionate care solutions designed to meet individual needs. With a commitment to excellence and trust, EULA Home Care helps seniors thrive at home with dignity and independence.

Media Contact
Company Name: EULA Home Care Agency
Contact Person: Davetta Williams
Email: Send Email
Phone: +1 704 549 8300
Address:8430 University Executive Park Dr Suite 606
City: Charlotte
State: NC
Country: United States
Website: http://www.eulahomecare.com

The 3D Urology and Prostate Clinics Announce Specialized Targeted Treatments for Prostate Conditions

The 3D Urology and Prostate Clinics present their unique 3D Targeted Therapy, offering patients a non-surgical, effective approach for various prostate diseases and related conditions.

The 3D Urology and Prostate Clinics are at the forefront of providing innovative therapeutic solutions for patients suffering from prostate conditions. Utilizing a distinctive approach, the clinics focus on addressing the root causes of diseases such as prostatitis, benign prostatic hyperplasia (BPH), and certain prostate cancers, aiming to alleviate symptoms and improve quality of life without the need for traditional surgery. This method is based on precise diagnosis and targeted delivery of medication, representing a significant shift in how these conditions can be managed and treated effectively. The 3D Urology and Prostate Clinics

Patients seeking specialized care for prostate issues can find comprehensive services at the 3D Urology Clinic. The clinics are dedicated to accurately diagnosing and treating a range of urological conditions affecting the prostate and surrounding areas. Their approach involves detailed 3D imaging and analysis to pinpoint the exact location and extent of the diseased tissues within the prostate. This precision is a cornerstone of their treatment philosophy, allowing for therapies to be customized precisely to the individual patient’s needs and the specific nature of their condition. By focusing on targeted diagnosis, the clinic ensures that subsequent treatment protocols are as effective as possible while minimizing impact on healthy tissues, leading to better patient outcomes and recovery experiences.

A core component of the treatment offered is the 3D prostate Targeted Treatment. This innovative methodology involves the targeted delivery of potent, natural medicine compounds directly to the affected areas within the prostate and surrounding tissues. Unlike systemic treatments that affect the entire body, this localized approach maximizes the concentration of medicine where it is needed most, significantly enhancing therapeutic efficacy while reducing potential side effects. The clinics have gathered numerous testimonials from patients who have experienced significant improvements in their symptoms and overall health after undergoing this specialized treatment. This targeted delivery system is designed to break down blockages, eliminate pathogens, and promote tissue repair, addressing inflammation and infection directly at the source.

The methodology employed by the clinics is known as 3D Targeted Therapy. This therapeutic system combines accurate 3D localization techniques with precise, direct drug delivery. The process typically begins with a thorough examination and 3D imaging to create a detailed map of the diseased area. Based on this map, a customized treatment plan is developed, involving the injection of specific, highly effective medications directly into the identified lesions or infected areas. This targeted approach allows the medicine to penetrate deep into the prostate tissue, breaking down stubborn blockages and biofilms that traditional treatments may fail to reach. The therapy is designed to be minimally invasive compared to surgery, offering patients a less stressful recovery period and often faster relief from chronic and painful symptoms associated with prostate diseases.

The treatments offered by The 3D Urology and Prostate Clinics represent a significant advancement in the field of urology, providing hope for patients with chronic or difficult-to-treat prostate conditions. By combining advanced 3D diagnostic imaging with precise, targeted delivery of medication, the clinics offer a unique and effective alternative to conventional therapies. This approach not only aims for symptom relief but also addresses the underlying pathological changes, promoting long-term prostate health and overall well-being for patients worldwide who travel to receive this specialized care.

About The 3D Urology and Prostate Clinics

The 3D Urology and Prostate Clinics specialize in diagnosing and treating prostate conditions like prostatitis, BPH, and prostate cancer using unique 3D targeted therapy, focusing on precise medicine delivery without surgery.

Media Contact
Company Name: The 3D Urology and Prostate Clinics
Contact Person: Miss Alisa Wang
Email: Send Email
Phone: +86-18673216429 (WhatsApp)
State: Hunan Province
Country: China
Website: http://www.3dprostatecure.com

Meet Raj Malik: The Woman Championing Ontario’s First-Time Homebuyers

In a province where the dream of homeownership can feel distant for many, Raj Malik is stepping forward to clear the fog. With over a decade of experience in Ontario’s real estate market, Raj has become a trusted guide for first-time homebuyers — and now, through her newest venture, First Time Home Buyer Realty, she’s expanding her mission to help the next generation secure their first keys.

For Raj, it’s not just about transactions; it’s about transformation. “I’ve worked with hundreds of clients over the years — young couples, new Canadians, single professionals — all feeling overwhelmed by the rising costs, tight supply, and complicated processes,” Raj says. “My goal is to empower them with the knowledge, tools, and support they need to confidently step into the market.”

First Time Home Buyer Realty focuses exclusively on first-time buyers across Ontario, from bustling Toronto condos to charming townhomes in the suburbs, and even the growing opportunities in freehold homes outside the core. Raj’s brokerage offers not only expert real estate advice but also access to a vast network of mortgage specialists, legal advisors, financial planners, and government incentive experts — all under one roof.

What sets Raj apart in a crowded industry is her laser-sharp focus on education and advocacy. “Buying your first home is one of the biggest financial moves you’ll ever make,” she explains. “Yet so many buyers jump in without fully understanding their options, their rights, or the programs available to help them — like the First-Time Home Buyer Incentive, tax credits, or land transfer tax rebates. That’s where we come in.”

This year, as market conditions shift and affordability shows signs of improvement, Raj sees a critical window of opportunity for first-time buyers who have been sitting on the sidelines. “We’re at an inflection point,” she says. “Interest rates are stabilizing, inventory is opening up, and prices in certain segments are softening. For many, 2025 could be the right time to make their move — but they need expert guidance to navigate the complexities.”

Raj’s commitment goes beyond individual transactions. Through workshops, webinars, and community partnerships, she’s building a movement that demystifies the homebuying process and gives people a real sense of agency. “I want my clients to feel seen, supported, and set up for long-term success — not just today, but for years to come.”

In an era where housing headlines often spell discouragement, Raj Malik offers something refreshingly different: optimism, backed by experience. As she leads First Time Home Buyer Realty into its next chapter, Ontario’s aspiring homeowners may just find the champion they’ve been waiting for.

For more details, contact Raj Malik at info@fthbr.com or call +1 647-984-3842.

For updates follow Raj Malik on Instagram @fthbrinc.brokerage

Media Contact
Company Name: First Time Home Buyer Realty
Contact Person: Raj Malik
Email: Send Email
Phone: +1 647-984-3842
City: Toronto
Country: Canada
Website: www.FTHBR.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Meet Raj Malik: The Woman Championing Ontario’s First-Time Homebuyers